Literature DB >> 10639594

The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells.

Z Y Shen1, J Shen, W J Cai, C Hong, M H Zheng.   

Abstract

It is accepted that inorganic arsenic trioxide is an inducer of apoptosis for many types of cancer. Our previous studies have demonstrated that arsenic trioxide induces apoptosis of esophageal carcinoma cells. Administration of arsenic trioxide results in the inhibition of growth and survival of tumor cells. Esophageal carcinoma cells treated with arsenic trioxide for 3 days demonstrated a typical morphological appearance of apoptosis. To further examine molecular mechanism of arsenic trioxide induced apoptosis of esophageal carcinoma cells, we have investigated the early changes of the apoptotic cell induced by arsenic trioxide. Our results indicated that arsenic trioxide induced apoptosis of esophageal carcinoma cells occurs as early as 2 h after treatment. Annexin-v staining has further proved that the phosphatidylserine is exposed at 2 h. The early morphological change of arsenic trioxide treated cells was in the mitochondria. Arsenic trioxide treated cells displayed aggregated mitochondria. It induces accumulation of high electron-density amorphous substances, swollen and disruption of mitochondria in oesophageal carcinoma cells after 2 h treatment. The alteration of mitochondria induced by arsenic trioxide seems to occur before the condensation of chromatin. Thus, our data demonstrated that the primary target of arsenic trioxide induced apoptosis of esophageal carcinoma cells may be the mitochondria. It is possible that arsenic trioxide is a mitochondriotoxic agent.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10639594     DOI: 10.3892/ijmm.5.2.155

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  22 in total

1.  Identification of differentially expressed proteins between human esophageal immortalized and carcinomatous cell lines by two-dimensional electrophoresis and MALDI-TOF-mass spectrometry.

Authors:  Xing-Dong Xiong; Li-Yan Xu; Zhong-Ying Shen; Wei-Jia Cai; Jian-Min Luo; Ya-Li Han; En-Min Li
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

2.  Separation and identification of differentially expressed nuclear matrix proteins between human esophageal immortalized and carcinomatous cell lines.

Authors:  Xing-Dong Xiong; En-Min Li; Li-Yan Xu; Hai-Bin Chen; Ling Chen; Wei-Jia Cai; Ya-Li Han; Zhong-Ying Shen; Yi Zeng
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

3.  Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth.

Authors:  Indira Jutooru; Gayathri Chadalapaka; Sandeep Sreevalsan; Ping Lei; Rola Barhoumi; Robert Burghardt; Stephen Safe
Journal:  Exp Cell Res       Date:  2010-05-08       Impact factor: 3.905

4.  Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetamidofluorene in rats.

Authors:  Bing Tan; Jie-Fei Huang; Qun Wei; Hong Zhang; Run-Zhou Ni
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

5.  Suppression of p53 and p21CIP1/WAF1 reduces arsenite-induced aneuploidy.

Authors:  Ana María Salazar; Heather L Miller; Samuel C McNeely; Monserrat Sordo; Patricia Ostrosky-Wegman; J Christopher States
Journal:  Chem Res Toxicol       Date:  2010-02-15       Impact factor: 3.739

6.  Arsenic trioxide modulates DNA synthesis and apoptosis in lung carcinoma cells.

Authors:  Alice M Walker; Jacqueline J Stevens; Kenneth Ndebele; Paul B Tchounwou
Journal:  Int J Environ Res Public Health       Date:  2010-05       Impact factor: 3.390

7.  Induction of hypoxia-inducible factor-1α inhibits drug-induced apoptosis in the human leukemic cell line HL-60.

Authors:  Yeon-Joo Yook; Young-Jin Seo; Hyoung Jin Kang; Sang-Hyeok Ko; Hee Young Shin; Jeong Jin Lee; Gajin Jeong; Hyo Seop Ahn
Journal:  Korean J Hematol       Date:  2010-09-30

8.  Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13.

Authors:  Olaf Merkel; Christoph Heyder; Daniela Asslaber; Frank Hamacher; Inge Tinhofer; Claudia Holler; Markus Stöcher; Andreas Prokesch; Christine Papak; Marcel Scheideler; Zlatko Trajanoski; Richard Greil
Journal:  J Mol Med (Berl)       Date:  2008-02-23       Impact factor: 4.599

9.  Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin.

Authors:  Majid Momeny; Majid Zakidizaji; Reza Ghasemi; Ahmad R Dehpour; Maryam Rahimi-Balaei; Yassan Abdolazimi; Ardeshir Ghavamzadeh; Kamran Alimoghaddam; Seyed H Ghaffari
Journal:  Med Oncol       Date:  2009-09-10       Impact factor: 3.064

10.  Arsenic trioxide suppresses paclitaxel-induced mitotic arrest.

Authors:  Q Duan; E Komissarova; W Dai
Journal:  Cell Prolif       Date:  2009-04-24       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.